Efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Final results from the Phase 3 SUNSHINE and SUNRISE trials

Alexa B. Kimball,Gregor B. E. Jemec,Afsaneh Alavi,Ziad Reguiai,Alice Gottlieb,Magdalena B. Wozniak,Lorenz Uhlmann,Angela Llobet Martinez,Claire Field,Shoba Ravichandran,Elisa Muscianisi

Journal of The American Academy of Dermatology（2023）

引用 0|浏览6

暂无评分

摘要

Background: Introduction: SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) were identical Phase 3, randomized, placebo-controlled, multi-center trials evaluating efficacy and safety of secukinumab in adults with moderate-to-severe hidradenitis suppurativa (HS) over 52 weeks.

查看译文

关键词

secukinumab,moderate-to-severe

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要